Autopsy report · NCT04430933

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

“Upon reviewing current available combo studies, the sponsor decided to prioritize different combo study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

NextCure, Inc.

Sponsor type

Industry

Conditions

Advanced or Metastatic Solid Tumors; Non-Small Cell Lung Cancer

Interventions

NC318; Pemetrexed/Carboplatin; Nab paclitaxel/Carboplatin; Docetaxel

Participants

0

Trials that died the same way

• Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
  “Phase 1completed; sponsor decided to change strategy to a combination study” (67% match in meaning)
• Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion
  “Sponsor preferred a better study design” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.